- PackSize
- 50ug/100ug
- Target
- CD152
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Humanized
- Isotype
- [V-kappa’-VH-h-CH2-CH3_V-kappa-VH’]2
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
- Species
- --
- Gene ID-1
- P16410 & Q15116
- Uniprot
- --
- Background
- Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).<br>• Cancer immunotherapy using checkpoint blockade., PMID:29567705<br/>• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870<br/>• Immune-related adverse events of checkpoint inhibitors., PMID:32382051<br/>• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845<br/>• Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113<br/>• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885<br/>• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160<br/>• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858<br/>• Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360<br/>• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704<br/>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --